JP7502846B2 - カリスポンジオリド、その類似体、およびそれらの使用 - Google Patents

カリスポンジオリド、その類似体、およびそれらの使用 Download PDF

Info

Publication number
JP7502846B2
JP7502846B2 JP2018562061A JP2018562061A JP7502846B2 JP 7502846 B2 JP7502846 B2 JP 7502846B2 JP 2018562061 A JP2018562061 A JP 2018562061A JP 2018562061 A JP2018562061 A JP 2018562061A JP 7502846 B2 JP7502846 B2 JP 7502846B2
Authority
JP
Japan
Prior art keywords
compound
formula
mmol
alkyl
equiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018562061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517474A (ja
JP2019517474A5 (enExample
Inventor
アラン ケー． ゴーシュ
ルーク エー． カッセケルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2019517474A publication Critical patent/JP2019517474A/ja
Publication of JP2019517474A5 publication Critical patent/JP2019517474A5/ja
Priority to JP2022097794A priority Critical patent/JP7641933B2/ja
Application granted granted Critical
Publication of JP7502846B2 publication Critical patent/JP7502846B2/ja
Priority to JP2024143999A priority patent/JP2024164181A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
JP2018562061A 2016-05-27 2017-05-26 カリスポンジオリド、その類似体、およびそれらの使用 Active JP7502846B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022097794A JP7641933B2 (ja) 2016-05-27 2022-06-17 カリスポンジオリド、その類似体、およびそれらの使用
JP2024143999A JP2024164181A (ja) 2016-05-27 2024-08-26 カリスポンジオリド、その類似体、およびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662342601P 2016-05-27 2016-05-27
US62/342,601 2016-05-27
PCT/US2017/034760 WO2017205791A1 (en) 2016-05-27 2017-05-26 Callyspongiolide, analogs thereof and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022097794A Division JP7641933B2 (ja) 2016-05-27 2022-06-17 カリスポンジオリド、その類似体、およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2019517474A JP2019517474A (ja) 2019-06-24
JP2019517474A5 JP2019517474A5 (enExample) 2020-06-18
JP7502846B2 true JP7502846B2 (ja) 2024-06-19

Family

ID=60411563

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018562061A Active JP7502846B2 (ja) 2016-05-27 2017-05-26 カリスポンジオリド、その類似体、およびそれらの使用
JP2022097794A Active JP7641933B2 (ja) 2016-05-27 2022-06-17 カリスポンジオリド、その類似体、およびそれらの使用
JP2024143999A Withdrawn JP2024164181A (ja) 2016-05-27 2024-08-26 カリスポンジオリド、その類似体、およびそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022097794A Active JP7641933B2 (ja) 2016-05-27 2022-06-17 カリスポンジオリド、その類似体、およびそれらの使用
JP2024143999A Withdrawn JP2024164181A (ja) 2016-05-27 2024-08-26 カリスポンジオリド、その類似体、およびそれらの使用

Country Status (7)

Country Link
US (1) US10875836B2 (enExample)
EP (1) EP3463579B1 (enExample)
JP (3) JP7502846B2 (enExample)
KR (1) KR102481799B1 (enExample)
CN (2) CN118812488A (enExample)
CA (1) CA3025178A1 (enExample)
WO (1) WO2017205791A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118812488A (zh) 2016-05-27 2024-10-22 普渡研究基金会 美丽海绵内酯、其类似物及其用途
WO2024021261A1 (zh) * 2022-07-29 2024-02-01 上海皓元医药股份有限公司 一种艾日布林中间体的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104177209B (zh) * 2014-08-05 2015-12-02 太原理工大学 一种芳基末端炔的制备方法
CN105777702B (zh) * 2016-03-31 2018-02-13 北京大学深圳研究生院 Callyspongiolide立体异构体的合成及抗癌应用
CN118812488A (zh) 2016-05-27 2024-10-22 普渡研究基金会 美丽海绵内酯、其类似物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ＺＨＯＵ， Ｊ． ｅｔ ａｌ．，Ｔｏｔａｌ Ｓｙｎｔｈｅｓｉｓ ａｎｄ Ｓｔｅｒｅｏｃｈｅｍｉｃａｌ Ａｓｓｉｇｎｍｅｎｔ ｏｆ Ｃａｌｌｙｓｐｏｎｇｉｏｌｉｄｅ，Ｊｏｕｒｎａｌ ｏｆ ｔｈｅ Ａｍｅｒｉｃａｎ Ｃｈｅｍｉｃａｌ Ｓｏｃｉｅｔｙ，２０１６年 ５月２６日，１３８（２２），ｐｐ． ６９４８－６９５１

Also Published As

Publication number Publication date
CA3025178A1 (en) 2017-11-30
JP2024164181A (ja) 2024-11-26
JP7641933B2 (ja) 2025-03-07
US20190218198A1 (en) 2019-07-18
KR20190012194A (ko) 2019-02-08
CN118812488A (zh) 2024-10-22
JP2022120170A (ja) 2022-08-17
JP2019517474A (ja) 2019-06-24
EP3463579A4 (en) 2019-11-27
KR102481799B1 (ko) 2022-12-26
EP3463579B1 (en) 2025-07-16
WO2017205791A1 (en) 2017-11-30
CN109195666A (zh) 2019-01-11
US10875836B2 (en) 2020-12-29
EP3463579A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
JP2024164181A (ja) カリスポンジオリド、その類似体、およびそれらの使用
ES2336937T3 (es) Sintesis de epotilonas, sus intermedios, analogos y usos.
JP6929903B2 (ja) 抗癌剤およびその調製方法
WO2018089621A1 (en) Tricyclic p2-ligand containing potent hiv-protease inhibitors against hiv/aids
US20190048009A1 (en) Methods for Preparing Bis-Tetrahydroisoquinoline-Containing Compounds
US11851441B2 (en) Anti-cancer agents and preparation thereof
US11230550B2 (en) Macrocyclic HIV-1 protease inhibitors and uses thereof
US20230136594A1 (en) Tricyclic p2-ligand containing potent hiv-protease inhibitors
HK40062614A (en) Anti-cancer agents and preparation thereof
WO2022040788A1 (en) Open-ring and lactone derivatives of unsaturated trihydroxy c-18 fatty acids and pharmaceutical compositions thereof having anti-cancer activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200511

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220617

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220617

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220727

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220930

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221003

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221125

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221130

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240313

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240607

R150 Certificate of patent or registration of utility model

Ref document number: 7502846

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150